Physician profile
Patrick J Bergin
NPI 1225309685
$9,781.98
in general payments reported to CMS, 2019-2025
37 companies · $694 in 2025
The $694 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,204 · 2020: $2,370 · 2021: $722 · 2022: $673 · 2023: $988 · 2024: $1,130 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,812.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $3,308.41 | 2019-2020 | |
| Boston Scientific Corporation | $1,802.57 | 2019-2025 | Avvigo Guidance System, Guidezilla, Accolade Sr |
| Abiomed | $987.09 | 2019-2025 | Impella |
| Abbott Laboratories | $907.80 | 2019-2025 | Assurity, Aveir, Gallant |
| Biotronik INC. | $459.65 | 2019-2024 | Acticor 7 Vr-T Dx |
| Novartis Pharmaceuticals Corporation | $355.14 | 2019-2025 | |
| Medtronic, INC. | $336.10 | 2021-2025 | Selectsecure, Micra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $192.32 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $128.38 | 2019-2024 | Farxiga |
| Penumbra, INC. | $107.55 | 2019 | |
| W. L. Gore & Associates, INC. | $107.17 | 2019 | |
| Celgene Corporation | $93.67 | 2022-2023 | Eliquis |
| Teleflex LLC | $80.39 | 2022-2023 | Vsi, Guideliner |
| Shockwave Medical, INC | $75.29 | 2022-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Philips North America LLC | $73.33 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $69.72 | 2019 | |
| Pfizer INC. | $66.29 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.18 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $57.84 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.53 | 2019 | |
| Amarin Pharma, INC. | $49.67 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $49.54 | 2023-2025 | Amvuttra |
| Angiodynamics, INC. | $48.50 | 2019 | |
| Medicomp INC | $48.18 | 2023 | Telepatch Cardiac Monitor |
| Cardiva Medical, INC. | $40.25 | 2022 | |
| Terumo Medical Corporation | $35.80 | 2019 | |
| Amgen INC. | $35.13 | 2019 | |
| Edwards Lifesciences Corporation | $24.14 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kowa Pharmaceuticals America, INC. | $17.14 | 2019 | |
| Novo Nordisk INC | $15.17 | 2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $14.02 | 2019 | |
| Lundbeck LLC | $13.85 | 2019 | |
| Impulse Dynamics (USA) INC. | $13.78 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.67 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $13.18 | 2023 | Inpefa |
| Gilead Sciences, INC. | $13.04 | 2019 | |
| Daiichi Sankyo INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Bergin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.